Literature DB >> 11538849

Angiotensin converting enzyme inhibition and the kidney.

N K Hollenberg1.   

Abstract

Angiotensin II (Ang II) induces a marked reduction in renal blood flow at doses well below those required to induce a pressor response, and as blood flow falls there is a decline in glomerular filtration rate and sodium excretion. This striking sensitivity of the renal blood supply led many workers to consider the possibility that angiotensin functions as a local renal hormone. As angiotensin converting enzyme (ACE) was found in particular abundance in the lung, it seemed reasonable to suspect that most of the conversion occurred there, and that the function of Ang II would be primarily systemic, rather than intrarenal. In this review, I will explore the evidence that has accumulated on these two possibilities, since they have important implications for our current understanding of normal kidney function and derangements of kidney function in disease.

Entities:  

Keywords:  NASA Discipline Number 21-50; NASA Discipline Regulatory Physiology; NASA Program Biomedical Research; Non-NASA Center

Mesh:

Substances:

Year:  1988        PMID: 11538849     DOI: 10.1097/00001573-198801001-00003

Source DB:  PubMed          Journal:  Curr Opin Cardiol        ISSN: 0268-4705            Impact factor:   2.161


  3 in total

1.  Selective beta-adrenoceptor partial agonist effects of pindolol and xamoterol on skeletal muscle assessed by plasma creatine kinase changes in healthy subjects.

Authors:  B Tomlinson; J M Cruickshank; Y Hayes; J C Renondin; J B Lui; B R Graham; A Jones; A D Lewis; B N Prichard
Journal:  Br J Clin Pharmacol       Date:  1990-11       Impact factor: 4.335

2.  Withdrawal phenomena after atenolol and bopindolol: hormonal changes in normal volunteers.

Authors:  R J Walden; B Tomlinson; B Graham; C Smith; D J Betteridge; B N Prichard
Journal:  Br J Clin Pharmacol       Date:  1990-10       Impact factor: 4.335

3.  Withdrawal phenomena after atenolol and bopindolol: haemodynamic responses in healthy volunteers.

Authors:  R J Walden; B Tomlinson; B Graham; J B Liu; B N Prichard
Journal:  Br J Clin Pharmacol       Date:  1990-10       Impact factor: 4.335

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.